E-LIB Suche - Ergebnisse für: Sicuranza, A

1

Tumor-Associated Macrophages in Multiple Myeloma: Key Role ..:

Cencini E ; Sicuranza A ; Ciofini S...
info:eu-repo/semantics/altIdentifier/pmid/37504315. , 2023

Link: https://hdl.handle.net/1..

2

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib..:

Sicuranza A ; Ferrigno I ; Abruzzese E...
info:eu-repo/semantics/altIdentifier/pmid/35178353. , 2022

Link: http://hdl.handle.net/24..

3

The third dose of mRNA SARS-CoV-2 vaccines enhances the spi..:

Fiorino, F ; Ciabattini, A ; Sicuranza, A...
info:eu-repo/semantics/altIdentifier/wos/WOS:000868203700001. , 2022

Link: https://hdl.handle.net/1..

4

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib..:

Sicuranza A ; Ferrigno I ; Abruzzese E...
info:eu-repo/semantics/altIdentifier/pmid/35178353. , 2022

Link: http://hdl.handle.net/23..

5

Overview of Anti-SARS-CoV-2 Immune Response Six Months afte..:

Gandolfo C ; Anichini G ; Mugnaini M...
info:eu-repo/semantics/altIdentifier/pmid/35214630. , 2022

Link: http://hdl.handle.net/11..

6

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib..:

Sicuranza A ; Ferrigno I ; Abruzzese E...
info:eu-repo/semantics/altIdentifier/pmid/35178353. , 2022

Link: https://hdl.handle.net/1..

7

Drug resistance and minimal residual disease in multiple my..:

Gozzetti A ; Ciofini S ; Sicuranza A...
info:eu-repo/semantics/altIdentifier/pmid/35582527. , 2022

Link: https://hdl.handle.net/1..

8

Fludarabine, high-dose cytarabine and idarubicin-based indu..:

Minetto P ; Candoni A ; Guolo F...
info:eu-repo/semantics/altIdentifier/wos/WOS:000605795400001. , 2021

Link: http://hdl.handle.net/11..

9

Fludarabine, high-dose cytarabine and idarubicin-based indu..:

Minetto P ; Candoni A ; Guolo F...
info:eu-repo/semantics/altIdentifier/wos/WOS:000605795400001. , 2021

Link: https://hdl.handle.net/1..

10

Fludarabine, high-dose cytarabine and idarubicin-based indu..:

Minetto P ; Candoni A ; Guolo F...
info:eu-repo/semantics/altIdentifier/pmid/33374216. , 2021

Link: http://hdl.handle.net/11..

11

The slower antibody response in myelofibrosis patients afte..:

Fiorino F ; Sicuranza A ; Ciabattini A...
info:eu-repo/semantics/altIdentifier/pmid/34680595. , 2021

Link: https://hdl.handle.net/1..

12

The role of tumor-associated macrophages in hematologic mal..:

Cencini E ; Fabbri A ; Sicuranza A..
info:eu-repo/semantics/altIdentifier/pmid/34298810. , 2021

Link: http://hdl.handle.net/11..

13

Favorable outcome in patients with chronic myeloid leukemia..:

O. Mulas ; G. Caocci ; M. Annunziata...
Congress of the European Hematology Association. , 2020

Link: https://hdl.handle.net/2..

14

Prospective evaluation of peripheral blood CD26+leukemia st..:

A. Sicuranza ; D. Raspadori ; P. Pacelli...
info:eu-repo/semantics/altIdentifier/wos/WOS:000649436400104. , 2020

Link: http://hdl.handle.net/24..

15

Venetoclax in association with decitabine as effective brid..:

Zappone E ; Cencini E ; Defina M...
info:eu-repo/semantics/altIdentifier/pmid/33088538. , 2020

Link: https://hdl.handle.net/1..